SAGE - Sage Therapeutics Inc Full Takeover Company Value

Brandmark of sagerx.com (SAGE)

Sage Therapeutics, Inc. (SAGE) is a leading developer in neuroscience, creating drugs for the treatment of CNS disorders and postpartum depression. This daily price chart on the GURU.Markets platform shows the enterprise value at , while weak capital inflows and challenges with new projects are reducing operational activity. Nevertheless, patents for highly specialized medications provide the company with a protected market position.

Sage Therapeutics Inc (SAGE) Total Company Value: for the period 07/04/2022 - 10/31/2026

Sage Therapeutics, Inc. - analytical breakdowns and key metrics (SAGE)

- market price and analyst price targets:
Stock Price Sage Therapeutics Inc.|SAGE - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Sage Therapeutics|SAGE - Enterprise Value
- company book value details:
Net Asset Value per Share Sage Therapeutics|SAGE - Company Book Value|Capitalization to Book Value Ratio sagerx.com|SAGE - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital Sage Therapeutics, Inc.|SAGE - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital sagerx.com|SAGE - Company Debts|Debt to Net Assets Ratio Sage Therapeutics|SAGE - Company Long-Term Debt|Short-Term Debt Sage Therapeutics|Interim Coverage Ratio sagerx.com
- earnings and market multiples details:
SAGE - Net Profit
Analysis of all company metrics:Sage Therapeutics Inc.
Manufactured product of Sage Therapeutics, Inc.

Enterprise Value (EV) combines market capitalization and net debt, determining the actual acquisition price of an asset while accounting for liquid reserves. An analysis of the real business value of Sage Therapeutics, Inc. (SAGE) allows for an assessment of the effectiveness of management's crisis transformation and the prioritization of R&D expenditures, helping investors distinguish temporary price volatility from a systemic impairment of the company's fundamentals.

Competitors of Sage Therapeutics, Inc. (SAGE)

Enterprise Value Biogen Inc BIIB|Neurocrine Biosciences Inc - Enterprise Value|Full Takeover Company Value Regencell Corp (RGC)|AXSM: Enterprise Value|Total Enterprise Value acadia-pharm.com (ACAD)|Total Company Value Xenon|Business Value VKTX (Viking Therapeutics Inc)|Enterprise Value SUPN|CPRX - Total Enterprise Value|Denali Therapeutics - Real Price to Acquire Entire Company|Enterprise Value harmonybiosciences.com HRMY|BHVN - Total Company Value|Value Adjusted for Debt and Cash AMLX (Amylyx Pharmaceuticals Inc)|Trevi Pharma (TRVI) - Total Company Value|Total Enterprise Value Praxis Corp (PRAX)|Total Company Value Anavex Life Sciences|ceribell.com (CBLL) - Company Buyout Price|Enterprise Value PRTA|Enterprise Value alector.com (ALEC)|Enterprise Value ANNX (Annexon Inc.)|Full Takeover Company Value Omeros Corp|Neurogene Inc. - Enterprise Value|Total Enterprise Value acimmune.com|VYGR (Voyager Therapeutics, Inc.) - Real Price to Acquire Entire Company|Neumora - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company SCLX|TVGN (Tevogen Bio Inc.) - Aggregate Business Value|Enterprise Value ACOG|CGTX (Cognition Therapeutics Inc.) - Value Adjusted for Debt and Cash|Enterprise Value IKT (Inhibikase Therapeutics, Inc.)|Cassava Sciences Inc (SAVA) - Total Enterprise Value|ASRT - Total Company Value|Value Adjusted for Debt and Cash COYA (Coya Therapeutics, Inc.)|VTGN: Enterprise Value|Ovid Therapeutics (OVID) - Enterprise Value|Total Company Value Acumen Pharmaceuticals, Inc.|CervoMed, Inc. - Full Business Value|Enterprise Value ATHE|CLNN - Total Enterprise Value|PepGen - Real Price to Acquire Entire Company|Enterprise Value Jupiter Neurosciences, Inc. JUNS|RLMD: Real Price to Acquire Entire Company|Annovis Bio Inc - Aggregate Business Value|GRCE: Enterprise Value|AIFF - Company Buyout Price|KLTO (ANEW Medical) - Enterprise Value|Real Price to Acquire Entire Company NeuroSense Therapeutics, Ltd. (NRSN)|Total Company Value Reviva Pharmaceuticals Holdings, Inc. (RVPH)|Company Buyout Price metaviatx.com|NeurAxis, Inc - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash HSDT|Passage Bio Corp - Enterprise Value|Company Buyout Price Neuphoria Therapeutics Inc. NEUP|Minerva Neurosciences, Inc. (NERV) - Total Company Value|Business Value ATHA|ADXN (Addex Therapeutics, Ltd.) - Enterprise Value|Real Price to Acquire Entire Company Alzamend (ALZN)|Real Price to Acquire Entire Company CYCN (Cyclerion Therapeutics)|Company Buyout Price protagenic.com|Total Company Value Pasithea Therapeutics Corp. KTTA|Company Buyout Price Cortigent Inc (CRGT)|Avenue Therapeutics, Inc - Enterprise Value|BCLI - Enterprise Value|CARA: Enterprise Value|Full Takeover Company Value chromocell.com CHRO|ELYM (Eliem Therapeutics, Inc.) - Enterprise Value|Total Enterprise Value Intra-Cellular ITCI|Total Company Value Longboard Pharma (LBPH)|Marinus Pharma - Business Value|Enterprise Value NKGN (NKGen Biotech, Inc.)|neurobopharma.com (NRBO) - Total Enterprise Value|SNPX: Real Price to Acquire Entire Company|TRVN - Enterprise Value|vigilneuro.com (VIGL) - Total Company Value|anewmeds.com - Value Adjusted for Debt and Cash|Total Company Value Cerevel Therapeutics